Dr. David Westaway – Misfolding of Brain Proteins Triggering Neurodegenerative Diseases

Dec 15, 2021 | Biology, Health and Medicine, Psychology and Neuroscience

Our DNA codes for proteins that are essential for the normal structure and function of our cells, tissues and organs. These proteins are folded in specific ways to facilitate these functions, but in disease states, this folding can go wrong. Dr. David Westaway from the University of Alberta in Canada investigates how and why protein misfolding occurs and how strains of misfolded proteins result in neurodegenerative diseases like dementia. His research is paving the way for novel therapies for these currently incurable and devasting conditions.

The Structure and Function of Proteins in Our Cells

Proteins are large and complex molecules that are found in every cell of the human body. They have an extensive number of different roles, ranging from making up structures within cells to carrying out specific functional roles or regulating other processes for normal body tissue and organ function. One example of a structural protein is called actin; the actin protein gives structure and support to cells and allows proper body movement. Antibodies that protect our bodies from infection are functional proteins, whereas enzymes are regulatory proteins that that help to carry out vital chemical reactions such as turning food into energy.

Each different protein is coded for by specific sequences of DNA, known as genes. Once cell machinery has deciphered these genes and determined which proteins are required, it joins together the relevant amino acids in the correct order to make these proteins. There are 20 different amino acids that can be stitched together in different orders and amounts to create a vast number of protein possibilities. This order of amino acids is known as a protein’s primary structure.

For proteins to function correctly, the secondary and tertiary structures, as well as the primary structure of the protein must be exact. The secondary structure is the local interactions between smaller sections of the protein whilst the tertiary structure is the overall, three-dimensional folding and structure of the protein. These three-dimensional shapes and their associated rigidity – or sometimes, aspects of their flexibility – are what allow a protein to perform its duties and keep cells healthy.

What Happens When Protein Folding Goes Wrong in the Brain?

Unfortunately, protein folding does not always go according to plan. In neurodegenerative brain diseases, a small group of proteins can be incorrectly folded and then cluster together. These clusters of proteins become sufficiently large that they can easily be seen with a simple microscope, and are observed to lie inside or next to brain cells.

To make matters worse, once these clusters have started to form, they can catalyse their own formation by taking new, normally folded proteins and disrupting their structure to be misfolded. In this process, the normal proteins are known as substrates and the misfolded proteins are collectively known as products.

Often, the result of a catalytic misfolding process is a neurodegenerative disease whereby brain function continues to decline over time. This loss of brain function can be associated with several different symptoms including memory loss, difficulty of movement, trouble speaking and unpredictable moods. Profound loss of reasoning and memory function is synonymous with the umbrella term dementia. One of the most common types of dementia is Alzheimer’s disease, which is well-known to affect a brain structure called the hippocampus while frontotemporal dementia produces degeneration nearer to the front of the brain. Apart from rare cases where substrate proteins are predisposed to misfold by a mutation, dementias are associated with older age and there is evidence that different lifestyle factors can either advance or stave off their development.

Unfortunately, around one-sixth of people over the age of 80 have dementia and the World Health Organization estimates 50 million people live with it worldwide. Whilst there are some medications available to ease the symptoms of dementia, the first generation of curatives is proving controversial and so, where possible, alternative treatments may be suggested. This might include cognitive stimulation therapy to improve brain function or cognitive rehabilitation to facilitate everyday tasks. Nevertheless, due to erosion of memory, intellect and normal behaviours, neurodegenerative diseases remain a difficult issue for many people and their families. Understanding the underlying events through research is an important step towards progressing different mechanism-based therapeutics.

Studying the Molecular Origins of Neurodegenerative Diseases

Unravelling the reasons for, mechanisms behind and solutions to neurodegenerative disease processes is Dr. David Westaway from the Centre for Prions and Protein Folding Diseases at the University of Alberta in Canada. He describes how the series of steps leading to the assembly of misfolded proteins is complex and the outcomes for any given misfolded protein are diverse. As a result, different types of protein clusters can form in the brain called ‘strains’ – and superficially similar to viral strains we are now all familiar with because they have certain predictable properties. Different misfolded protein strains can react differently to medications too; whereas one strain may diminish and respond well to a certain treatment in petri-dish experiments, another strain may partially or completely evade treatment.

According to Dr. Westaway, ‘My laboratory focuses on these issues and events for two proteins of interest – the cellular prion protein and the protein tau’. The cellular prion protein is found on the surface of cells in many different tissues and organs but especially in the central and peripheral nervous systems. As the brain is a part of the central nervous system, when the cellular surface protein becomes misfolded and builds up it causes neurodegenerative diseases. These are collectively referred to as prion diseases. Tau proteins are also found in abundance in the central nervous system and neurons, and abnormal accumulations of tau are associated with Alzheimer’s and Pick’s disease, which are also neurodegenerative syndromes. The collective name for tau diseases is tauopathies.

Misfolding of the Cellular Prion Protein

Before scientists were aware of different strains of neurodegenerative disease proteins, it was generally believed that one type of amino acid chain could only result in one type of three-dimensional folding and one type of misfolding. This perspective has now been superseded and Dr. Westaway explains that there is ‘another layer of complexity – the misfolding outcomes for a protein can be diverse and can change depending on which part of the molecule is being considered.’

This has previously been studied and documented in a protein called amyloid precursor protein in relation to Alzheimer’s disease. Following on from this, Dr. Westaway and his team have looked into cellular prion protein and how it is involved in disease development. They have studied mutant types of the cellular prion protein that are predisposed to misfolding and inevitably cause disease.

A mutant protein has single or multiple amino acids replacing those that are standard, resulting in an abnormal protein. This is due to genes that are themselves coded abnormally or alternatively, it is due to a mistake in protein quality control somewhere along the production line in cells. Dr. Westaway is interested in finding and developing chemicals and drugs that could control misfolding events due to mutant proteins. This could lead to exciting developments in therapeutics for multiple neurodegenerative diseases.

Strains of the Tau Protein Lead to Different types of Dementias

Dr. Westaway has also moved forward our understanding of changes in tau in relation to different types of tauopathy. Describing his work, Dr. Westaway notes, ‘for the protein tau, using susceptible mice made by genetic engineering and a chemical test of misfolding, we have shown that one type of substrate molecule can create a collection of different misfolded variants; this work was carried out with our collaborator Jiri G. Safar, MD. As elapsed time increased beyond two-thirds of the natural lifespan of these mice, this mixture of variants evolved into two or three clearly recognisable strains of misfolded tau protein.’

This means that he was able to demonstrate one protein misfolding into multiple strains in a real-world example. In animal models of disease (e.g., mice), disease progression is sometimes deliberately accelerated to make experiments quicker, not to mention less expensive. However, this can mean that the processes that result in different tau strains are difficult to detect. Therefore, Dr. Westaway utilised a ‘slow’ model of neurodegenerative disease and this allowed him to study the evolution of events that lead up to strain formation.

The team found that, in a human context that shares the same type of tau protein as the mouse disease model, the different tau protein strains were associated with different types of dementia that affect the frontal lobes of the brain (collectively known as frontotemporal dementias). Here, the suspicion was – and has now been verified by chemical analyses of human and animal model samples – that the differences that could be seen in patients behaviours originated from slightly different forms of abnormal tau.

‘My laboratory is tracking down the chemical processes and cells which participate in the evolution of toxic misfolded forms of the tau protein’, says Dr. Westaway. If these processes can be thoroughly defined, they can be targeted by novel therapies for the disease. Blocking the formation and diversification of these unwanted strains through drugs could be a promising method of preventing and blocking neurodegenerative diseases.

Continuing the Vital Work: New Funding

Recently, Dr. Westaway and his colleagues in the Centre for Prions and Protein Folding Diseases, in the Neuroscience and Mental Health Institute and in the Department of Physics at the University of Alberta, have secured novel federal, provincial and for-profit funding of an incredible $9.5 million. This backing came thanks to an investment initiative of over half a billion dollars led by Canada’s Prime Minister, Justin Trudeau. The goal of distributing this funding is to sustain innovative, scientific research and discovery within the country. This exciting financial support will help Dr. Westaway and his colleagues carry on advanced research into neurodegenerative diseases.

Already, Dr. Westaway and his team have made impressive strides into deepening our understanding of protein folding and misfolding and how they impact health and disease. By elucidating the processes that result in protein strains and consequent neurodegenerative disease, he is beginning to point towards possible new therapies for the future. This provides important hope for the millions of people suffering from dementia worldwide.






Dr. David Westaway
Centre for Prions and Protein Folding Diseases
University of Alberta
Edmonton, Alberta

Dr. David Westaway completed his BSc in Biochemistry at the University of Sussex in the UK, and went on to achieve a PhD in the Biochemistry Department of Imperial College at the University of London. Having received multiple awards in his field and filled numerous academic positions, Dr. Westaway is now a Professor in the Department of Medicine (Neurology) at the University of Alberta in Canada. He is also the Director of the Centre for Prions and Protein Folding Disease at the University of Alberta, which is where he carries out his research into what happens when protein folding goes wrong in our cells.


E: david.westaway@ualberta.ca

W: www.prioncentre.ca


N Daude, C Kim, S-G Kang, et al., Diverse, evolving conformer populations drive distinct phenotypes in frontotemporal lobar degeneration caused by the same MAPT‑P301L mutation, Acta Neuropathologica, 2020, 139(6), 1045–1070.

AR Castle, N Daude, S Gilch, D Westaway, Application of high-throughput, capillary-based Western analysis to modulated cleavage of the cellular prion protein, Journal of Biological Chemistry, 2019, 294(8), 2642–5291.

A Lau, A McDonald, N Daude, et al., Octarepeat region flexibility impacts prion function, endoproteolysis and disease manifestation, EMBO Molecular Medicine, 2015, 7(3), 339–356.


We encourage all formats of sharing and republishing of our articles. Whether you want to host on your website, publication or blog, we welcome this. Find out more

Creative Commons Licence (CC BY 4.0)

This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

What does this mean?

Share: You can copy and redistribute the material in any medium or format

Adapt: You can change, and build upon the material for any purpose, even commercially.

Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.




Dr Uwe Grether – Targeting the Cannabinoid CB2 Receptor for Novel Anti-inflammatory Therapeutics

Dr Uwe Grether – Targeting the Cannabinoid CB2 Receptor for Novel Anti-inflammatory Therapeutics

On the surface of many of our cells, intriguing receptors called cannabinoid receptors reach out into their environment. The CB2 subtype of this receptor family is expressed largely on our immune cells and plays an important role in inflammatory responses, making it a promising target for anti-inflammatory therapeutics. To produce effective drugs, the molecules that bind to the CB2 receptor, known as ligands, need to be characterised. Dr Uwe Grether from F. Hoffmann-La Roche Ltd has dedicated his research to discovering useful CB2 receptor ligands and utilising them in the development of novel anti-inflammatory therapeutics.

Dr Uwe Grether – Targeting the Cannabinoid CB2 Receptor for Novel Anti-inflammatory Therapeutics

Professor Peter Breunig – The Significance of Nok Culture Sculptures in Nigerian Prehistory

Peter Breunig is a Professor of Archaeology at Goethe University in Frankfurt, Germany. He has spent much of his recent career conducting in-depth analyses around the Nok culture, a prehistoric society based in central Nigeria. Much of his research has focused on uncovering the mystery surrounding elaborate terracotta sculptures, made by the Nok people over 2,500 years ago. Whilst there is much speculation around their purpose, Peter Breunig and his team have identified a spatial proximity to burial sites, indicating their usage in funeral rituals.

The Biomedical Entrepreneurship Skills Development Program (BEEP): Educating a New Generation of Medical Innovators

The Biomedical Entrepreneurship Skills Development Program (BEEP): Educating a New Generation of Medical Innovators

Innovative, new technologies are rapidly being introduced into the medical world, as scientists and inventors continually discover solutions to all kinds of health issues. However, comprehensive education in medical product development, business process and strategy is distinctly lacking for science students who aspire to become commercial medical innovators and entrepreneurs. Entrepreneurially minded professionals at the New York University Grossman School of Medicine developed, implemented, and integrated programs to train early scientists in the business side of science to accelerate the pace of commercialisation and encourage individuals to pursue venture creation and entrepreneurship to impact highly relevant healthcare solutions.

Jenna Rackovan – Helping Fish Near Power Plants to Just Keep Swimming

Jenna Rackovan – Helping Fish Near Power Plants to Just Keep Swimming

Cleaner, greener electricity is imperative to meet the demands of a burgeoning population. Many power plants rely on vast quantities of water to cool their systems and maintain proper operation. But sucking up vast quantities of water can pose a risk for fish and other aquatic animals. Balancing the operational efficiency of power plant cooling systems with environmental protection requires a dedicated team of engineers and fisheries biologists. In their recent research, Jenna Rackovan and her colleagues at Alden Research Laboratory in Massachusetts optimise the use of travelling water screens for fish protection.